295 related articles for article (PubMed ID: 31121933)
21. Molecular characterization of enterovirus-A71 in children with acute flaccid paralysis in the Philippines.
Apostol LN; Shimizu H; Suzuki A; Umami RN; Jiao MMA; Tandoc A; Saito M; Lupisan S; Oshitani H
BMC Infect Dis; 2019 May; 19(1):370. PubMed ID: 31046684
[TBL] [Abstract][Full Text] [Related]
22. Secretory Carrier Membrane Protein 3 Interacts with 3A Viral Protein of Enterovirus and Participates in Viral Replication.
Lu JY; Brewer G; Li ML; Lin KZ; Huang CC; Yen LC; Lin JY
Microbiol Spectr; 2021 Sep; 9(1):e0047521. PubMed ID: 34378951
[TBL] [Abstract][Full Text] [Related]
23. Characterization of Plaque Variants and the Involvement of Quasi-Species in a Population of EV-A71.
Mandary MB; Masomian M; Ong SK; Poh CL
Viruses; 2020 Jun; 12(6):. PubMed ID: 32560288
[TBL] [Abstract][Full Text] [Related]
24. Amino acid variation at VP1-145 of enterovirus A71 determines the viral infectivity and receptor usage in a primary human intestinal model.
Aknouch I; García-Rodríguez I; Giugliano FP; Calitz C; Koen G; van Eijk H; Johannessson N; Rebers S; Brouwer L; Muncan V; Stittelaar KJ; Pajkrt D; Wolthers KC; Sridhar A
Front Microbiol; 2023; 14():1045587. PubMed ID: 37138595
[TBL] [Abstract][Full Text] [Related]
25. A Mouse Model for Infection with Enterovirus A71 in Small Extracellular Vesicles.
Gu J; Wu J; Cao Y; Zou X; Jia X; Yin Y; Shen L; Fang D; Mao L
mSphere; 2020 Jul; 5(4):. PubMed ID: 32611697
[TBL] [Abstract][Full Text] [Related]
26. Enterovirus A71 Induces Neurological Diseases and Dynamic Variants in Oral Infection of Human SCARB2-Transgenic Weaned Mice.
Lin JY; Weng KF; Chang CK; Gong YN; Huang GJ; Lee HL; Chen YC; Huang CC; Lu JY; Huang PN; Chiang HJ; Chen CM; Shih SR
J Virol; 2021 Oct; 95(21):e0089721. PubMed ID: 34379497
[TBL] [Abstract][Full Text] [Related]
27. A severe pediatric infection with a novel enterovirus A71 strain, Thuringia, Germany.
Karrasch M; Fischer E; Scholten M; Sauerbrei A; Henke A; Renz DM; Mentzel HJ; Böer K; Böttcher S; Diedrich S; Krumbholz A; Zell R
J Clin Virol; 2016 Nov; 84():90-95. PubMed ID: 27771495
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo studies of a potent capsid-binding inhibitor of enterovirus 71.
Ho JY; Chern JH; Hsieh CF; Liu ST; Liu CJ; Wang YS; Kuo TW; Hsu SJ; Yeh TK; Shih SR; Hsieh PW; Chiu CH; Horng JT
J Antimicrob Chemother; 2016 Jul; 71(7):1922-32. PubMed ID: 27098012
[TBL] [Abstract][Full Text] [Related]
29. Functional Insights into Silymarin as an Antiviral Agent against Enterovirus A71 (EV-A71).
Lalani S; Masomian M; Poh CL
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445463
[TBL] [Abstract][Full Text] [Related]
30. A monoclonal antibody to ameliorate central nervous system infection and improve survival in a murine model of human Enterovirus-A71 encephalomyelitis.
Tan SH; Ong KC; Perera D; Wong KT
Antiviral Res; 2016 Aug; 132():196-203. PubMed ID: 27340013
[TBL] [Abstract][Full Text] [Related]
31. Molecular Docking of SP40 Peptide towards Cellular Receptors for Enterovirus 71 (EV-A71).
Masomian M; Lalani S; Poh CL
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770987
[TBL] [Abstract][Full Text] [Related]
32. 3,4-Dicaffeoylquinic Acid from the Medicinal Plant
Hsieh CF; Chen YL; Lin GH; Chan YF; Hsieh PW; Horng JT
J Virol; 2022 Apr; 96(7):e0054221. PubMed ID: 35319229
[TBL] [Abstract][Full Text] [Related]
33. Recommendations for enterovirus diagnostics and characterisation within and beyond Europe.
Harvala H; Broberg E; Benschop K; Berginc N; Ladhani S; Susi P; Christiansen C; McKenna J; Allen D; Makiello P; McAllister G; Carmen M; Zakikhany K; Dyrdak R; Nielsen X; Madsen T; Paul J; Moore C; von Eije K; Piralla A; Carlier M; Vanoverschelde L; Poelman R; Anton A; López-Labrador FX; Pellegrinelli L; Keeren K; Maier M; Cassidy H; Derdas S; Savolainen-Kopra C; Diedrich S; Nordbø S; Buesa J; Bailly JL; Baldanti F; MacAdam A; Mirand A; Dudman S; Schuffenecker I; Kadambari S; Neyts J; Griffiths MJ; Richter J; Margaretto C; Govind S; Morley U; Adams O; Krokstad S; Dean J; Pons-Salort M; Prochazka B; Cabrerizo M; Majumdar M; Nebbia G; Wiewel M; Cottrell S; Coyle P; Martin J; Moore C; Midgley S; Horby P; Wolthers K; Simmonds P; Niesters H; Fischer TK
J Clin Virol; 2018 Apr; 101():11-17. PubMed ID: 29414181
[TBL] [Abstract][Full Text] [Related]
34. Antiviral activity of Mulberroside C against enterovirus A71 in vitro and in vivo.
Cao Y; Lei E; Li L; Ren J; He X; Yang J; Wang S
Eur J Pharmacol; 2021 Sep; 906():174204. PubMed ID: 34051220
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanism of L-SP40 peptide and in vivo efficacy against EV-A71 in neonatal mice.
Lalani S; Tan SH; Tan KO; Lim HX; Ong KC; Wong KT; Poh CL
Life Sci; 2021 Dec; 287():120097. PubMed ID: 34715144
[TBL] [Abstract][Full Text] [Related]
36. Mutations in VP2 and VP1 capsid proteins increase infectivity and mouse lethality of enterovirus 71 by virus binding and RNA accumulation enhancement.
Huang SW; Wang YF; Yu CK; Su IJ; Wang JR
Virology; 2012 Jan; 422(1):132-43. PubMed ID: 22078110
[TBL] [Abstract][Full Text] [Related]
37. Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology.
Yang YT; Chow YH; Hsiao KN; Hu KC; Chiang JR; Wu SC; Chong P; Liu CC
Antiviral Res; 2016 Aug; 132():225-32. PubMed ID: 27387826
[TBL] [Abstract][Full Text] [Related]
38. Immune responses against enterovirus A71 infection: Implications for vaccine success.
Aw-Yong KL; NikNadia NMN; Tan CW; Sam IC; Chan YF
Rev Med Virol; 2019 Sep; 29(5):e2073. PubMed ID: 31369184
[TBL] [Abstract][Full Text] [Related]
39. Adaptation and Virulence of Enterovirus-A71.
Kobayashi K; Koike S
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452525
[TBL] [Abstract][Full Text] [Related]
40. Viral determinants that drive Enterovirus-A71 fitness and virulence.
Ang PY; Chong CWH; Alonso S
Emerg Microbes Infect; 2021 Dec; 10(1):713-724. PubMed ID: 33745413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
